Appointments at Sigma-Aldrich, Novavax and Pfizer’s CEO taking on an additional role – People on the move
George Miller has been appointed as senior vice president (VP), general counsel and secretary of Sigma-Aldrich. Miller has 20 years of corporate legal experience at companies including Novartis and Federal Express Corporation.
Amsterdam Molecular Therapeutics (AMT) has appointed Jorn Aldag as CEO. From 2001 to 2008 Aldag served as CEO of Evotec and is also chairman of the board of molecular partners in Switzerland.
Novavax has appointed Stanley Erck to its board’s corporate governance, compensation and finance committees. Erck has previously served as CEO of several vaccine and immunology products companies and joined the Novavax board in June.
Asher Rubin has been appointed as executive VP, chief legal officer and secretary of Intrexon. Rubin has previously worked at Hogan & Hartson, Guilford Pharmaceuticals and has been active in the proceedings of the Biotechnology Industry Organization (BIO).
immatics biotechnologies has appointed Carsten Reinhardt as chief medical officer. Reinhardt joins immatics from Micromet. He has also worked at Hoffman-La Roche, where he worked on Herceptin (trastuzumab), and held positions at various academic institutions.
George Church has been appointed as director of Sigma-Aldrich. Church is a professor of genetics at Harvard Medical School and has been granted more than 10 US patents.
Pfizer’s CEO Jeff Kindler has been elected to the New York Fed’s board as a class B director. Kindler is serving the unexpired portion of a three-year term ending December 31.
John Kelley has resigned as president and chief operating officer of The Medicines Company. Kelley has left “to pursue other interests” and will remain as special advisor to the company’s CEO until December 31 at the earliest.
